A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma
Oncology and Therapy · 2024-12 · 12 (4) · 803-815
DOI: 10.1007/s40487-024-00304-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Therapy, online erschienen am 01.10.2024. Verfasst von Diana Rofail und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA. diana.rofail@regeneron.com. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals.
Abstract (Originalsprache)
INTRODUCTION: Although cutaneous squamous cell carcinoma (CSCC) is the second most common type of skin cancer, research describing the patient experience is limited. This study sought to create a conceptual model of non-metastatic disease, to assess patient-reported outcome (PRO) instruments commonly used in CSCC against this model, and to develop a patient-relevant measurement strategy for evaluating the benefit of new therapies. METHODS: Researchers conducted a literature review, a review of patient blogs, and interviews with dermatologists to draft the conceptual model. A total of 22 patients with CSCC participated in 60-min phone interviews, which were subsequently transcribed, coded, and analyzed; the conceptual model was then updated. PRO instruments used in CSCC were assessed for content validity on the basis of this. RESULTS: The CSCC patient experience includes physical symptoms, psychological impacts, and behavior changes. Existing PRO instruments were assessed against the conceptual model using targeted subdomains considered to be relevant for assessing clinical benefit. Four modules of the FACE-Q® Skin Cancer instrument, plus de novo items developed for concepts not assessed by the FACE-Q® [lesion symptoms, negative treatment effects (including symptomatic), and experience of care], provide the best coverage for the concepts of interest hypothesized to show the benefit of novel treatments. CONCLUSIONS: This research provides a comprehensive understanding of the experience of patients with non-metastatic CSCC, and the effects of its treatment. It also identifies unmet needs in a subgroup of patients reporting negative treatment experiences. Further cognitive debriefing and psychometric analysis of de novo items are warranted for applications in clinical research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA. diana.rofail@regeneron.com.
- Modus Outcomes, A THREAD Company, Cambridge, MA, USA.
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.
Förderung
- Regeneron Pharmaceuticals
Zitieren
APA
Rofail, D., Ciesluk, A., Lovell, T., Marquis, P., Fury, M. G., & Chen, C. I. (2024). A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma. Oncology and Therapy, 12(4), 803-815. https://doi.org/10.1007/s40487-024-00304-4
Vancouver
Rofail D, Ciesluk A, Lovell T, Marquis P, Fury MG, Chen CI. A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma. Oncology and Therapy. 2024;12(4):803-815. doi:10.1007/s40487-024-00304-4
BibTeX
@article{Rofail2024,
author = {Rofail, Diana and Ciesluk, Anna and Lovell, Teya and Marquis, Patrick and Fury, Matthew G and Chen, Chieh-I},
title = {A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma},
journal = {Oncology and Therapy},
year = {2024},
volume = {12},
number = {4},
pages = {803--815},
doi = {10.1007/s40487-024-00304-4}
}
EUVIMED